Scarica l'app Stockscreener
0.00
100.00%
-15.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Definium Therapeutics Inc Borsa (MNMD) Ultime notizie
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day - Business Wire
DFTX: DT120 targets major psychiatric disorders with pivotal data and commercial launch readiness in 2024 - TradingView
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge? - simplywall.st
DFTX: DT-120 aims to transform psychiatric care with rapid, durable relief and broad market potential - TradingView
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Iovance Biotherapeutics (IOVA) - The Globe and Mail
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move - Benzinga
Definium Therapeutics Announces New Employee Inducement GrantsApril 20, 2026 - BioSpace
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order - MEXC Exchange
Definium Therapeutics stock hits 52-week high at 25.63 USD - Investing.com
Definium Therapeutics (DFTX) Stock Hits 52-Week High as Trump Backs Psychedelic Medicine Research - CoinCentral
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump's Psychedelic Research Order - Blockonomi
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order -- Update - Moomoo
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Benzinga
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains - Seeking Alpha
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics (DFTX) Is Up 5.3% After White House Signals Support For Psychedelic Research - simplywall.st
Definium Therapeutics (DFTX) Stock Climbs Following White House Psychedelic Policy Shift - MEXC
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments | MEXC News - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments - MEXC
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health - marketscreener.com
Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health - TradingView
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments - The Joplin Globe
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026 - TechStock²
Trump signs executive order on psychedelics (ATAI:NASDAQ) - Seeking Alpha
Trump Trade: President to sign order on psychedelic used for PTSD - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? - Yahoo Finance
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones (NASDAQ:DFTX) - Seeking Alpha
DFTX Initiates Coverage On Stifel -- Rating Set to Buy - GuruFocus
Can an LSD candidate do for anxiety what Spravato did for depression? - Pharma Voice
Stifel Initiates Definium Therapeutics at Buy With $30 Price Target - marketscreener.com
Definium Therapeutics Conference Slot Tests Psychedelic Phase III And Funding Story - Sahm
DFTX Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Stifel initiates Definium stock with buy rating on anxiety drug - Investing.com UK
Stifel initiates Definium stock with buy rating on anxiety drug By Investing.com - Investing.com Australia
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data - MarketBeat
Definium Therapeutics Price Target Raised to $38.00/Share From $25.00 by Canaccord Genuity - Moomoo
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighStill a Buy? - MarketBeat
DFTX Options Chain — NASDAQ:DFTX - TradingView
DFTX Options Volatility — NASDAQ:DFTX - TradingView
Definium Therapeutics Sees Insider Stock Selling - 富途牛牛
DFTX: Definium Therapeutics, Inc.Income Statment - Zacks Investment Research
All News for DFTX : Definium Therapeutics, Inc. - Zacks Investment Research
2.53%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):